Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing.

MLA

Noack, Darius, et al. “Homozygous CDKN2A/B Deletions in Low- and High-Grade Glioma: A Meta-Analysis of Individual Patient Data and Predictive Values of P16 Immunohistochemistry Testing.” Acta Neuropathologica Communications, vol. 12, no. 1, Nov. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s40478-024-01889-7.

APA

Noack, D., Wach, J., Barrantes-Freer, A., Nicolay, N. H., Güresir, E., & Seidel, C. (2024). Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing. Acta Neuropathologica Communications, 12(1), 1–11. https://doi.org/10.1186/s40478-024-01889-7

Chicago

Noack, Darius, Johannes Wach, Alonso Barrantes-Freer, Nils H. Nicolay, Erdem Güresir, and Clemens Seidel. 2024. “Homozygous CDKN2A/B Deletions in Low- and High-Grade Glioma: A Meta-Analysis of Individual Patient Data and Predictive Values of P16 Immunohistochemistry Testing.” Acta Neuropathologica Communications 12 (1): 1–11. doi:10.1186/s40478-024-01889-7.